查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
噬菌体疗法市场:各治疗领域，各给药途径，各地区:产业趋势与全球预测，2022年～2035年
市场调查报告书
商品编码
1172474

噬菌体疗法市场:各治疗领域，各给药途径，各地区:产业趋势与全球预测，2022年～2035年

Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography : Industry Trends and Global Forecasts, 2022-2035
出版日期: | 出版商: Roots Analysis | 英文 220 Pages | 商品交期: 最快1-2个工作天内

价格

本报告提供全球噬菌体疗法市场相关调查，市场概要，以及各治疗领域，各给药途径，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 摘要整理

第3章 简介

  • 章概要
  • 噬菌体的历史性演进
  • 噬菌体的生物学
  • 噬菌体疗法的简介
  • 噬菌体疗法的应用
  • 噬菌体疗法的优点
  • 噬菌体疗法的限制
  • 结论

第4章 市场形势噬菌体疗法:市场风景

  • 章概要
  • 噬菌体治疗药:药物开发平台
  • 噬菌体相关技术讯息

第5章 噬菌体疗法:开发商的风景

第6章 企业及药物简介

  • 章概要
  • Eliava BioPreparations
  • Micreos
  • NPO Microgen
  • ContraFect
  • Adaptive Phage Therapeutics
  • Phagelux
  • Pherecydes Pharma

第7章 临床试验分析

  • 章概要
  • 范围与调查手法
  • 噬菌体治疗市场:临床试验分析

第8章 专利分析

第9章 出版物基准分析

第10章 学术津贴分析

第11章 资金筹措投资分析

第12章 伙伴关係和合作

  • 章概要
  • 伙伴关係模式
  • 噬菌体疗法:伙伴关係和合作的清单

第13章 新兴企业的健康指数

第14章 市场预测机会分析

  • 章概要
  • 范围与前提
  • 预测调查手法
  • 全球噬菌体治疗药市场，2022年～2035年
  • 噬菌体治疗药市场，2022年～2035年:各治疗领域
  • 噬菌体治疗药市场，2022年～2035年:各给药途径
  • 噬菌体治疗药市场，2022年～2035年:各地区

第15章 结论

第16章 执行见解

第17章 附录I:表格形式的资料

第18章 附录II:公司及组织的清单

Product Code: RA100388

INTRODUCTION

Antimicrobial resistance (AMR) has been identified as one of the greatest threats to public health. According to the Centers of Disease Control and Prevention, more than 2.8 million cases of AMR infections are identified in the United States on an annual basis, leading to death of more than 35,000 people. , Further, World Health Organization (WHO) has estimated that, by 2050, the increasing burden of such infections is expected to increase the healthcare expenditure by USD 1.2 trillion, annually. To address this situation, WHO has developed a global action plan for raising public awareness, reducing the incidence of infections, and optimizing the use of antimicrobial drugs, paving the way for the development of alternative anti-infectious modalities. , One such example of these modalities includes bacteriophage therapies. These therapeutics have been used in healthcare for over a century, providing an alternative approach to target the disease-causing multi-drug resistant bacteria; however, their use has been limited. With the growing need for therapies targeting AMR infections, bacteriophage therapeutics are now gaining more traction. These therapeutics tend to cause minimal drug toxicity, replicate themselves at the site of action, have reduced side-effects, and have the potential to self-decompose when the infection causing bacteria have been exterminated.

Given the afore-mentioned advantages of bacteriophage therapeutics and promising insights from the ongoing research, various clinical trials have been registered for the clinical evaluation of bacteriophage therapies. In fact, with the widespread participation of stakeholders in the research and development of bacteriophage therapeutics, clinical studies evaluating bacteriophage therapeutics have increased at a growth rate of more than 30% over the last few years. Moreover, the volume of affiliated scientific literature (2,200+ related publications since 2018) has also increased, demonstrating the growing popularity of bacteriophage therapeutics and related technologies. Given the encouraging results, this domain has piqued the interest of many private and public investors who have invested more than USD 1 billion over the last few years. With increasing R&D efforts, promising clinical data, and financial support from investors, we anticipate the bacteriophage therapeutics market to witness notable growth in the mid to long term.

SCOPE OF THE REPORT

The "Bacteriophage Therapeutics Market - Distribution by Therapeutic Area (Infectious Diseases, Oncological Disorders, and Other Disorders), Route of Administration (Oral, Topical, Rectal and Intravenous), and Geography (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the bacteriophage therapeutics market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

  • A summary of the key insights from the bacteriophage therapeutics market. It offers a high-level view on the current state of the market and its likely evolution in the mid to long term.
  • A general overview of the historical evolution of bacteriophages and their biology. It also includes a detailed discussion on applications of bacteriophage therapy. The chapter concludes with a discussion on the various advantages and limitations associated with the bacteriophage therapy.
  • A detailed overview of the overall market landscape of bacteriophage therapeutics, including information on their current status of development (marketed, clinical, preclinical and discovery), key therapeutic areas (infectious diseases, oncological disorders, and other disorders), type of bacterial strain (Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Salmonella, Streptococcus, Acinetobacter baumannii and others), target disease indication (lung infection, bone infection, urinary tract infection, gastrointestinal infection, bacterial infection, blood infection, other disorders, and multiple infections), type of therapy (monotherapy, combination therapy, and both), route of administration (oral route, topical route, rectal route and intravenous route), and information on bacteriophage related technologies.
  • An overview of the current status of the market with respect to the players engaged in the manufacturing of bacteriophage therapeutics, featuring information on the year of establishment, company size, location of headquarters, and leading developers.
  • Elaborate profiles of the prominent players engaged in the development of bacteriophage therapeutics (shortlisted based on the number of drugs progressed to advanced phases of development). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, and a section on recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, trial phase, enrolled patient population, study design, type of sponsor / collaborator, most active players (in terms of number of registered trials), registered trials, and geographical region (by number of registered trials and number of enrolled patient population).
  • An in-depth analysis of the various patents that have been filed / granted related to bacteriophage therapeutics. It includes information on key parameters, such as type of patent (granted patents, patent applications and others), publication year, application year, number of granted patents and patent applications, geographical distribution, Cooperative Patent Classification (CPC) symbols, and type of applicant. It also highlights the leading industry and non-industry players and individual assignees (in terms of number of patents filed / granted).
  • An in-depth analysis of various publications for bacteriophage therapeutics, based on several relevant parameters, such as year of publication, type of article, popular keywords, most popular publishers (in terms of number of publications), key journals (in terms of number of articles published and journal impact factor). It also highlights benchmarking of the publications to develop more insightful opinions on the recent trends related to research and development in this area.
  • A detailed study of the various grants that have been awarded to research institutes engaged in projects related to bacteriophage therapeutics, since 2017, highlighting various important parameters, such as year of award, amount awarded, funding institute, support period, grant type, purpose of grant, focus area, type of recipient organization, and leading recipient organizations.
  • An in-depth analysis of the investments made, including grants, venture capital financing, initial public offering, secondary offering, private placement, equity and debt funding, at various stages of development, in companies that are focused on developing bacteriophage therapeutics.
  • A detailed study of the recent collaborations and partnership established in this domain since 2017, including the details of deals that were / are focused on the development of bacteriophage therapeutics, which were analyzed based on several parameters such as year of partnership, type of partnership (research and development agreement, product development agreement, licensing agreement, merger / acquisition, commercialization agreement, manufacturing agreement, clinical trial agreement, supply agreement, distribution agreement and other agreement), therapeutic area (infectious diseases, hepatological disorders, chronic inflammatory disorders, skin disorders and women's health), application areas (human health, animal health, diagnostic test, aquaculture, food safety, food safety and environment protection and livestock farming), and regional distribution of partnerships.
  • An analysis of the various start-ups engaged in the development of bacteriophage therapeutics, based on relevant parameters, such as pipeline strength, pipeline maturity, indication diversity, number of patents, financial support and partnership activity

One of the key objectives of the report was to estimate the current market size and potential growth opportunities, over the coming 13 years. Based on various parameters, such as target patient population, region specific adoption rates, and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market in the short to mid-term and long term, for the period 2022-2035. In order to evaluate the current and future opportunity associated with the bacteriophage therapeutics market, our year-wise projections have been segmented based on several relevant parameters such as, target therapeutic area (infectious diseases, oncological disorders, and other disorders), route of administration (oral, topical, rectal and intravenous), and geographical region (North America, Europe, Asia Pacific, and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Antoine Culot (Chief Executive Officer, Rime Bioinformatics)
  • Iddo Weiner (Senior Director, Head of Data-Science, BiomX)
  • Mathieu Medina (Project Leader, Hospices Civils De Lyon)
  • Mohammadreza Azizkhani (Independent Consultant)

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the period 2022-2035, the report also provides our independent views on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

  • Who are the leading players engaged in the development of bacteriophage therapeutics?
  • What are the various bacteriophage therapy candidates in the current development pipeline?
  • Which geographies are the most active in conducting clinical trials related to bacteriophage therapeutics?
  • What is the focus area of various publications related to bacteriophage therapeutics?
  • Which partnership models are commonly adopted by industry and non-industry stakeholders?
  • What are the different initiatives undertaken by start-ups for the development of bacteriophage therapeutics in the recent past?
  • How is the current and future market opportunity, likely to be distributed across key market segments?

CHAPTER OUTLINES

  • Chapter 2: provides a summary of the key insights from the bacteriophage therapeutics market. It offers a high-level view on the current state of the market and its likely evolution in the mid to long term.
  • Chapter 3: is a general overview of the historical evolution of bacteriophages and their biology. It includes a detailed discussion on applications of bacteriophage therapy. The chapter then concludes with a discussion on the various advantages and limitations associated with the bacteriophage therapy.
  • Chapter 4: provides information on over 100 bacteriophage therapeutics that are currently approved or are in different stages of development. It features a detailed analysis of marketed / under development molecules, based on current status of development (marketed, phase III, Phase II/III, phase II, phase I/II, phase I, preclinical / discovery stage) of lead candidates, therapeutic area (infectious diseases, oncological disorders, and other disorders), target bacterial strain (Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Salmonella, Streptococcus, Acinetobacter baumannii and others), target disease indication (lung infection, bone infection, urinary tract infection, gastrointestinal infection, bacterial infection, blood infection, other disorders, and multiple infections), type of therapy (monotherapy and combination therapy), and route of administration (oral route, topical route, rectal route and intravenous route).
  • Chapter 5: provides a detailed overview of close to 40 companies that are actively involved in the manufacturing of bacteriophage therapeutics. The chapter provides details on the year of establishment, company size, location of headquarters, and leading developers.
  • Chapter 6: features detailed profiles of prominent players having capability to manufacture bacteriophage therapeutics (shortlisted based on the number of drugs progressed to advanced phases of development). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.
  • Chapter 7: provides information on more than 40 completed, ongoing and planned clinical trials of bacteriophage therapeutics, based on different parameters, such as trial registration year, trial phase, trial recruitment status, study design, target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.
  • Chapter 8: provides an overview of the various patents that have been filed / granted for therapies related to bacteriophage therapeutics, till mid-July 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, application year, number of granted patents and patent applications, geographical distribution, Cooperative Patent Classification (CPC) symbols, and type of applicant. It also highlights the leading industry and non-industry players and individual assignees (in terms of number of patents filed / granted).
  • Chapter 9: provides information on various publications that were published related to bacteriophage therapeutics, such as year of publication, type of article, popular keywords, most popular publishers (in terms of number of publications), key journals (in terms of number of articles published and journal impact factor). It also highlights benchmarking of the publications to develop more insightful opinions on the recent trends related to research and development (R&D) in this area.
  • Chapter 10: provides information on the various grants that were awarded to research institutes conducting projects related to bacteriophage therapeutics, since 2017. The analysis also highlighting various important parameters, such as year of award, amount awarded, funding institute, support period, grant type, purpose of grant, focus area, type of recipient organization, and leading recipient organizations.
  • Chapter 11: presents details on various investments received by various players engaged in the development of bacteriophage therapeutics, till August 2022. It includes analysis based on relevant parameters, such as year of investment, amount invested, type of funding (grant, venture series, initial public offering, secondary offering, private placement, equity and debt financing), most active players (based on number of funding rounds and number of instance), and regional distribution of amount invested.
  • Chapter 12: provides a detailed study of the recent collaborations and partnerships inked in this domain since 2017, including the details of deals that were / are focused on the development of bacteriophage therapeutics, which were analyzed based on several parameters such as year of partnership, type of partnership (research and development agreement, product development agreement, licensing agreement, merger / acquisition, commercialization agreement, manufacturing agreement, clinical trial agreement, supply agreement, distribution agreement and other agreement), therapeutic area (infectious diseases, hepatological disorders, chronic inflammatory disorders, skin disorders and women's health), application areas (human health, animal health, diagnostic test, aquaculture, food safety, food safety and environment protection and livestock farming), and regional distribution of partnerships.
  • Chapter 13: features an analysis of the various start-ups engaged in manufacturing of bacteriophage therapeutics, based on relevant parameters, such as pipeline strength, pipeline maturity, indication diversity, number of patents, financial support and partnership activity
  • Chapter 14: presents a comprehensive market forecast analysis, highlighting the likely growth of bacteriophage therapeutics market till the year 2035. We have segmented the financial opportunity on the basis of therapeutic area (infectious diseases, oncological disorders, and other disorders), route of administration (oral route, topical route, rectal route and intravenous route), and geography (North America, Europe, Asia-Pacific, and rest of the world).
  • Chapter 15: is the summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of the bacteriophage therapeutics market.
  • Chapter 16: is a collection of the transcripts of interviews conducted with the key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations with Antoine Culot, (Chief Executive Officer, Rime Bioinformatics), Iddo Weiner (Senior Director, Head of Data-Science, BiomX), Mathieu Medina (Project Leader, Hospices Civils De Lyon), and Mohammadreza Azizkhani (Independent Consultant).
  • Chapter 17: is an appendix that contains tabulated data and numbers for all the figures in the report.
  • Chapter 18: is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentations
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Historical Evolution of Bacteriophages
  • 3.3. Biology of Bacteriophages
  • 3.4. Introduction to Bacteriophage Therapy
  • 3.5. Applications of Bacteriophage Therapy
  • 3.6. Advantages of Bacteriophage Therapy
  • 3.7. Limitations of Bacteriophage Therapy
  • 3.8. Conclusion

4. BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Bacteriophage Therapeutics: Drug Pipeline
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Therapeutic Area
    • 4.2.3. Analysis by Phase of Development and Therapeutic Area
    • 4.2.4. Analysis by Targeted Bacterial Strain
    • 4.2.5. Analysis by Target Disease Indication
    • 4.2.6. Analysis by Type of Therapy
    • 4.2.7. Analysis by Route of Administration
  • 4.3. Information on Bacteriophage Related Technologies

5. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Bacteriophage Therapeutics: List of Developers
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Location of Headquarters
    • 5.2.4. Analysis by Company Size and Location of Headquarters
    • 5.2.5. Leading Developers: Analysis by Number of Bacteriophage Therapeutics

6. COMPANY AND DRUG PROFILES

  • 6.1. Chapter Overview
  • 6.2. Eliava BioPreparations
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Pipeline Overview
      • 6.2.3.1. Pyo Bacteriophage
      • 6.2.3.2. Intesti Bacteriophage
      • 6.2.3.3. SES Bacteriophage
      • 6.2.3.4. Staphylococcal Bacteriophage
      • 6.2.3.5. Fersisi Bacteriophage
      • 6.2.3.6. Enko Bacteriophage
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Micreos
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Pipeline Overview
      • 6.3.3.1. PhageGuard Listex
      • 6.3.3.2. PhageGuard S
      • 6.3.3.3. PhageGuard E
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. NPO Microgen
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Pipeline Overview
      • 6.4.3.1. E. coli-Proteus Bacteriophage
      • 6.4.3.2. Streptococcus Bacteriophage
      • 6.4.3.3. Complex Pyobacteriophage
      • 6.4.3.4. Klebsiella Purified Polyvalent Bacteriophage
      • 6.4.3.5. Sextaphag
      • 6.4.3.6. Dysentery Bacteriophage
      • 6.4.3.7. Intesti
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. ContraFect
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3. Pipeline Overview
      • 6.5.3.1. Exebacase (CF-301)
      • 6.5.3.2. CF-296
      • 6.5.3.3. CF-370
      • 6.5.3.4. Gram-Negative Lysins
      • 6.5.3.5. Amurins
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. Adaptive Phage Therapeutics
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Pipeline Overview
      • 6.6.3.1. Bacteriophage Therapeutics
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. Phagelux
    • 6.7.1. Company Overview
    • 6.7.2. Financial Information
    • 6.7.3. Pipeline Overview
      • 6.7.3.1. PGX-0100
      • 6.7.3.2. BactelideTM
      • 6.7.3.3. BactelideTM
    • 6.7.4. Recent Developments and Future Outlook
  • 6.8. Pherecydes Pharma
    • 6.8.1. Company Overview
    • 6.8.2. Financial Information
    • 6.8.3. Pipeline Overview
      • 6.8.3.1. Bacteriophage Therapeutics
    • 6.8.4. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Bacteriophage Therapeutics Market: Clinical Trial Analysis
    • 7.3.1. Analysis by Trial Registration Year
    • 7.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
    • 7.3.3. Analysis by Trial Status
    • 7.3.4. Analysis by Trial Phase and Enrolled Patient Population
    • 7.3.5. Analysis by Study Design
    • 7.3.6. Analysis by Type of Sponsor / Collaborator
    • 7.3.7. Most Active Players: Analysis by Number of Registered Trials
    • 7.3.8. Regional Analysis
      • 7.3.8.1. Analysis by Number of Registered Trials
      • 7.3.8.2. Analysis by Enrolled Patient Population

8. PATENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Bacteriophage Therapeutics: Patent Analysis
    • 8.3.1. Analysis by Publication Year
    • 8.3.2. Analysis by Patent Application Year
    • 8.3.3. Analysis by Annual Number of Granted Patent(s) and Patent Application(s)
    • 8.3.4. Analysis by Geography
    • 8.3.5. Analysis by CPC Symbols
    • 8.3.6. Analysis by Type of Applicant
    • 8.3.7. Leading Players: Analysis by Number of Patents
  • 8.4. Bacteriophage Therapeutics: Patent Benchmarking
    • 8.4.1. Analysis by Patent Characteristics
  • 8.5. Bacteriophage Therapeutics: Patent Valuation
  • 8.6. List of Leading Patents

9. PUBLICATION BENCHMARKING ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
    • 9.2.1. Analysis by Year of Publication
    • 9.2.2. Analysis by Type of Article
    • 9.2.3. Analysis by Popular Keywords
    • 9.2.4. Popular Publishers: Analysis by Number of Publications
    • 9.2.5. Popular Journals: Analysis by Number of Publications
    • 9.2.6. Popular Journals: Analysis by Journal Impact Factor
    • 9.2.7. Publications: Timeline Analysi
  • 9.3. Publication Benchmarking

10. ACADEMIC GRANTS ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Bacteriophage Therapeutics: Academic Grant Analysis
    • 10.3.1. Analysis by Year of Grant Award
    • 10.3.2. Analysis by Amount Awarded
    • 10.3.3. Analysis by Administering Institute Center
    • 10.3.4. Analysis by Support Period
    • 10.3.5. Analysis by Funding Institute Center and Support Period
    • 10.3.6. Analysis by Type of Grant Application
    • 10.3.7. Analysis by Purpose of Grant Award
    • 10.3.8. Analysis by Activity Code
    • 10.3.9. Word Cloud Analysis: Emerging Focus Areas
    • 10.3.10. Analysis by Study Section Involved
    • 10.3.11. Popular NIH Departments: Analysis by Number of Grants
    • 10.3.12. Analysis by Type of Recipient Organization
    • 10.3.13. Prominent Program Officers: Analysis by Number of Grants
    • 10.3.14. Popular Recipient Organizations: Analysis by Number of Grants
    • 10.3.15. Regional Distribution of Recipient Organizations

11. FUNDING AND INVESTMENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Types of Funding
  • 11.3. Bacteriophage Therapeutics Market: List of Funding and Investments
    • 11.3.1. Analysis by Year of Investment
    • 11.3.2. Analysis by Amount Invested
    • 11.3.3. Analysis by Type of Funding
    • 11.3.4. Most Active Players: Analysis by Number of Funding Rounds and Amount Raised
    • 11.3.5. Investors Analysis
    • 11.3.6. Regional Distribution by Amount Invested
  • 11.4. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS

  • 12.1. Chapter Overview
  • 12.2. Partnership Models
  • 12.3. Bacteriophage Therapeutics: List of Partnerships and Collaborations
    • 12.3.1. Analysis by Year of Partnership
    • 12.3.2. Analysis by Type of Partnership
    • 12.3.3. Analysis by Year of Partnership and Type of Partner
    • 12.3.4. Analysis by Therapeutic Area
    • 12.3.5. Analysis by Application Area
    • 12.3.6. Most Active Players: Analysis by Number of Partnerships
    • 12.3.7. Regional Analysis
      • 12.3.7.1. Intercontinental and Intracontinental Agreements

13. START-UP HEALTH INDEXING

  • 13.1. Chapter Overview
  • 13.2. Bacteriophage Therapeutics Developers: Start-ups
    • 13.2.1. Analysis by Location of Headquarters
  • 13.3. Benchmarking of Start-ups
    • 13.3.1. Analysis by Pipeline Strength
    • 13.3.2. Analysis by Pipeline Maturity
    • 13.3.3. Analysis by Indication Diversity
    • 13.3.4. Analysis by Number of Patents
    • 13.3.5. Analysis by Funding Amount
    • 13.3.6. Analysis by Partnership Activity
    • 13.3.7. Start-ups Health Indexing: Roots Analysis Perspective

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Scope and Assumptions
  • 14.3. Forecast Methodology
  • 14.4. Global Bacteriophage Therapeutics Market, 2022-2035
  • 14.4. 1. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Therapeutic Area
      • 14.4.1.1. Bacteriophage Therapeutics Market for Gastrointestinal Infectious, 2022-2035
      • 14.4.1.2. Bacteriophage Therapeutics Market for Bacterial Dysentery, 2022-2035
      • 14.4.1.3. Bacteriophage Therapeutics Market for Multiple Infections, 2022-2035
  • 14.4. 2. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Route of Administration
      • 14.5.2.1. Bacteriophage Therapeutics Market for Oral Therapies, 2022-2035
      • 14.5.2.2. Bacteriophage Therapeutics Market for Rectal Therapies, 2022-2035
      • 14.5.2.3. Bacteriophage Therapeutics Market for Intravesical Therapies, 2022-2035
      • 14.5.2.4. Bacteriophage Therapeutics Market for Topical Therapies, 2022-2035
  • 14.4. 3. Bacteriophage Therapeutics Market, 2022-2035: Distribution by Geography
      • 14.6.3.1. Bacteriophage Therapeutics in North America, 2022-2035
      • 14.6.3.2. Bacteriophage Therapeutics in Europe, 2022-2035

15. CONCLUSION

16. EXECUTIVE INSIGHTS

  • 16.1. Chapter Overview
  • 16.2. Rime Bioinformatics
    • 16.2.1. Company Snapshot
    • 16.2.2. Interview Transcript: Antoine Culot, Chief Executive Officer
  • 16.3. BiomX
    • 16.3.1. Company Snapshot
    • 16.3.2. Interview Transcript: Iddo Weiner, Senior Director, Head of Data-Science
  • 16.4. Hospices Civils De Lyon
    • 16.4.1. Organization Snapshot
    • 16.4.2. Interview Transcript: Mathieu Medina, Project Leader
  • 16.5. Independent Consultant
    • 16.5.1. Interview Transcript: Mohammadreza Azizkhani, Scientific Researcher

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

  • Table 4.1 Bacteriophage Therapeutics: Information on Developer, Phase of Development, Bacterial Target, Target Disease Indication, Therapeutic Area
  • Table 4.2 Bacteriophage Therapeutics: Information on Type of Therapy and Route of Administration
  • Table 4.2 Bacteriophage Therapeutics: Information on Bacteriophage Related Technologies
  • Table 5.1 Bacteriophage Therapeutics: List of Developers
  • Table 6.1 Eliava BioPreparations: Company Overview
  • Table 6.2 Eliava BioPreparations: Pipeline Overview
  • Table 6.3 Micreos: Company Overview
  • Table 6.4 Micreos: Pipeline Overview
  • Table 6.5 NPO Microgen: Company Overview
  • Table 6.6 NPO Microgen: Pipeline Overview
  • Table 6.7 ContraFect: Company Overview
  • Table 6.8 ContraFect: Pipeline Overview
  • Table 6.9 Adaptive Phage Therapeutics: Company Overview
  • Table 6.10 Adaptive Phage Therapeutics: Pipeline Overview
  • Table 6.11 Phagelux: Company Overview
  • Table 6.12 Phagelux: Pipeline Overview
  • Table 6.13 Pherecydes Pharma: Company Overview
  • Table 6.4 Pherecydes Pharma: Pipeline Overview
  • Table 8.1 List of Top CPC Sections
  • Table 8.2 List of Top CPC Symbols
  • Table 8.3 List of Top CPC Codes
  • Table 8.4 Patent Analysis: Summary of Benchmarking
  • Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 8.6 Patent Portfolio: List of Leading Patents (by Number of Citations)
  • Table 9.1 Publication Benchmarking: List of Top 50 Publications
  • Table 11.1 Bacteriophage Therapeutics: List of Funding and Investments, 2017-2022
  • Table 11.2 Funding and Investment Analysis: Summary of Investment
  • Table 12.1 Bacteriophage Therapeutics: List of Partnerships and Collaborations, 2017-2022
  • Table 17.1 Bacteriophage Therapeutics: Distribution by Phase of Development
  • Table 17.2 Bacteriophage Therapeutics: Distribution by Therapeutic Area
  • Table 17.3 Bacteriophage Therapeutics: Distribution by Phase of Development and Therapeutic Area
  • Table 17.4 Bacteriophage Therapeutics: Distribution by Targeted Bacterial Strain
  • Table 17.5 Bacteriophage Therapeutics: Distribution by Target Disease Indication
  • Table 17.6 Bacteriophage Therapeutics: Distribution by Type of Therapy
  • Table 17.7 Bacteriophage Therapeutics: Distribution by Route of Administration
  • Table 17.8 Bacteriophage Therapeutics Developers: Distribution by Year of Establishment
  • Table 17.9 Bacteriophage Therapeutics Developers: Distribution by Company Size
  • Table 17.10 Bacteriophage Therapeutics Developers: Distribution by Location of Headquarters
  • Table 17.11 Bacteriophage Therapeutics Developers: Distribution by Company Size and Location of Headquarters
  • Table 17.12 Leading Developers: Distribution by Number of Bacteriophage Therapeutics
  • Table 17.13 Clinical Trial Analysis: Scope and Methodology
  • Table 17.14 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
  • Table 17.15 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, 2010-2022
  • Table 17.16 Clinical Trial Analysis: Distribution by Trial Status
  • Table 17.17 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
  • Table 17.18 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
  • Table 17.19 Clinical Trial Analysis: Distribution by Study Design
  • Table 17.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 17.21 Most Active Players: Distribution by Number of Registered Trials
  • Table 17.22 Geographical Analysis: Distribution by Number of Registered Trials
  • Table 17.23 Geographical Analysis: Distribution by Enrolled Patient Population
  • Table 17.24 Patent Analysis: Distribution by Type of Patent
  • Table 17.25 Patent Analysis: Cumulative Distribution by Publication Year, Till 2022
  • Table 17.26 Patent Analysis: Cumulative Distribution by Patent Application Year, Till 2022
  • Table 17.27 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent(s) and Patent Application(s), Till 2022
  • Table 17.28 Patent Analysis: Distribution by Geography
  • Table 17.29 Patent Analysis: Distribution by CPC Symbols
  • Table 17.30 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, Till 2022
  • Table 17.31 Leading Industry Players: Distribution by Number of Patents
  • Table 17.32 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 17.33 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Table 17.34 Patent Analysis: Distribution by Patent Age
  • Table 17.35 Patent Valuation Analysis
  • Table 17.36 Publication Benchmarking Analysis: Cumulative Year-wise Trend, 2018-2022
  • Table 17.37 Publication Benchmarking Analysis: Distribution by Type of Article
  • Table 17.38 Publication Benchmarking Analysis: Distribution by Popular Keywords
  • Table 17.39 Popular Publishers: Distribution by Number of Publications
  • Table 17.40 Popular Journals: Distribution by Number of Publications
  • Table 17.41 Popular Journals: Distribution by Journal Impact Factor
  • Table 17.42 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, 2017-2022
  • Table 17.43 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), 2017-2022
  • Table 17.44 Grant Analysis: Distribution by Administering Institute Center
  • Table 17.45 Grant Analysis: Distribution by Support Period
  • Table 17.46 Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Table 17.47 Grant Analysis: Distribution by Type of Grant Application
  • Table 17.49 Grant Analysis: Distribution by Purpose of Grant Award
  • Table 17.49 Grant Analysis: Distribution by Activity Code
  • Table 17.50 Grant Analysis: Distribution by Study Section Involved
  • Table 17.51 Popular NIH Departments: Distribution by Number of Grants
  • Table 17.52 Grant Analysis: Distribution by Types of Recipient Organization
  • Table 17.53 Most Prominent Program Officers: Distribution by Number of Grants
  • Table 17.54 Popular Recipient Organization: Distribution by Number of Grants
  • Table 17.55 Grant Analysis: Regional Distribution of Recipient Organization
  • Table 17.56 Funding and Investment Analysis: Cumulative Year-wise Trend, 2017-2022
  • Table 17.57 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2017-2022
  • Table 17.58 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2017-2022
  • Table 17.59 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, 2017-2022
  • Table 17.60 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
  • Table 17.61 Most Active Investors: Distribution by Number of Instances
  • Table 17.62 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, 2017-2022
  • Table 17.63 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2017-2022
  • Table 17.64 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 17.65 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
  • Table 17.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, 2017-2022
  • Table 17.67 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 17.68 Partnerships and Collaborations: Distribution by Application Area
  • Table 17.69 Most Active Players: Distribution by Number of Partnerships
  • Table 17.70 Partnerships and Collaborations: Regional Distribution
  • Table 17.71 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 17.72 Startup-Health Indexing: Distribution by Location of Headquarters
  • Table 17.73 Startup-Health Indexing: Distribution by Pipeline Strength
  • Table 17.74 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Table 17.75 Startup-Health Indexing: Distribution by Indication Diversity

Table 17. 76 Startup-Health Indexing: Distribution by Number of Patents

  • Table 17.77 Startup-Health Indexing: Distribution by Funding Amount
  • Table 17.78 Start-up Health Indexing: Roots Analysis Perspective
  • Table 17.79 Start-up Health Indexing: Leading Companies
  • Table 17.80 Global Bacteriophage Therapeutics Market, 2022-2035 (USD Million)
  • Table 17.81 Bacteriophage Therapeutics Market for Market for Infectious Diseases, 2022-2035 (USD Million)
  • Table 17.82 Bacteriophage Therapeutics Market for Oncological Diseases, 2022-2035 (USD Million) 2022-2035 (USD Million)
  • Table 17.83 Bacteriophage Therapeutics Market for Other Disorders, 2022-2035 (USD Million)
  • Table 17.84 Bacteriophage Therapeutics Market for Oral Therapies, 2022-2035 (USD Million)
  • Table 17.85 Bacteriophage Therapeutics Market for Topical Therapies, 2022-2035 (USD Million)
  • Table 17.86 Bacteriophage Therapeutics Market for Rectal Therapies, 2022-2035 (USD Million)
  • Table 17.87 Bacteriophage Therapeutics Market for Intravenous Therapies, 2022-2035 (USD Million)
  • Table 17.88 Bacteriophage Therapeutics Market in North America, 2022-2035 (USD Million)
  • Table 17.89 Bacteriophage Therapeutics Market in Europe, 2022-2035 (USD Million)
  • Table 17.90 Bacteriophage Therapeutics Market in Asia Pacific, 2022-2035 (USD Million)
  • Table 17.91 Bacteriophage Therapeutics Market in Rest of the World, 2022-2035 (USD Million)
  • Table 17.92 Complex Pyobacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.93 Dysentery Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.94 E.coli-Proteus Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.95 Enko BACTERIOPHAGE: Sales Forecast till 2035 (USD Million)
  • Table 17.96 Fersisi BACTERIOPHAGE: Sales Forecast till 2035 (USD Million)
  • Table 17.97 Intesti: Sales Forecast till 2035 (USD Million)
  • Table 17.98 Intesti Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.99 Klebsiella Purified Polyvalent Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.100 Pyo Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.101 SES Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.102 Sextaphag®: Sales Forecast till 2035 (USD Million)
  • Table 17.103 Staphylococcal Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.104 Streptococcus Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.105 PYO Phage Streptococcus Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Table 17.106 Unnamed Streptococcus Bacteriophage (Adaptive Phage Therapeutics): Sales Forecast till 2035 (USD Million)

LIST OF FIGURES

  • Figure 3.1 History Timeline of Bacteriophage
  • Figure 3.2 Bacteriophage Replication Cycle
  • Figure 3.3 Advantages of Bacteriophage Therapy
  • Figure 3.4 Limitations of Bacteriophage Therapy
  • Figure 4.1 Bacteriophage Therapeutics: Distribution by Phase of Development
  • Figure 4.2 Bacteriophage Therapeutics: Distribution by Therapeutic Area
  • Figure 4.3 Bacteriophage Therapeutics: Distribution by Phase of Development and Therapeutic Area
  • Figure 4.4 Bacteriophage Therapeutics: Distribution by Targeted Bacterial Strain
  • Figure 4.5 Bacteriophage Therapeutics: Distribution by Target Disease Indication
  • Figure 4.6 Bacteriophage Therapeutics: Distribution by Type of Therapy
  • Figure 4.7 Bacteriophage Therapeutics: Distribution by Route of Administration
  • Figure 5.1 Bacteriophage Therapeutics Developers: Distribution by Year of Establishment
  • Figure 5.2 Bacteriophage Therapeutics Developers: Distribution by Company Size
  • Figure 5.3 Bacteriophage Therapeutics Developers: Distribution by Location of Headquarters
  • Figure 5.4 Bacteriophage Therapeutics Developers: Distribution by Company Size and Location of Headquarters
  • Figure 5.5 Leading Developers: Distribution by Number of Bacteriophage Therapeutics
  • Figure 7.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
  • Figure 7.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, 2010-2022
  • Figure 7.4 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 7.5 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Status
  • Figure 7.6 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
  • Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 7.10 Most Active Players: Distribution by Number of Registered Trials
  • Figure 7.11 Geographical Analysis: Distribution by Number of Registered Trials
  • Figure 7.12 Geographical Analysis: Distribution by Enrolled Patient Population
  • Figure 8.1 Patent Analysis: Distribution by Type of Patent
  • Figure 8.2 Patent Analysis: Cumulative Distribution by Publication Year, Till 2022
  • Figure 8.3 Patent Analysis: Cumulative Distribution by Patent Application Year, Till 2022
  • Figure 8.4 Patent Analysis: Year-wise Distribution by Annual Number of Granted Patent(s) and Patent Application(s), Till 2022
  • Figure 8.5 Patent Analysis: Distribution by Geography
  • Figure 8.6 Patent Analysis: Distribution by CPC Symbols
  • Figure 8.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, Till 2022
  • Figure 8.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 8.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 8.10 Leading Industry Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Figure 8.11 Patent Analysis: Distribution by Patent Age
  • Figure 8.12 Patent Valuation Analysis
  • Figure 9.1 Publication Benchmarking Analysis: Cumulative Year-wise Trend, 2018-2022
  • Figure 9.2 Publication Benchmarking Analysis: Distribution by Type of Article
  • Figure 9.3 Publication Benchmarking Analysis: Distribution by Popular Keywords
  • Figure 9.4 Popular Publishers: Distribution by Number of Publications
  • Figure 9.5 Popular Journals: Distribution by Number of Publications
  • Figure 9.6 Popular Journals: Distribution by Journal Impact Factor
  • Figure 9.7 Timeline Analysis: Distribution by Article Type and Average Time to Publish
  • Figure 9.8 Timeline Analysis: Distribution by Journal Impact Factor and Average Time to Publish
  • Figure 9.9 Timeline Analysis: Distribution by Type of Article and Maximum Time to Publish
  • Figure 9.10 Timeline Analysis: Distribution by Journal Impact Factor and Maximum Time to Publish
  • Figure 9.11 Publication Benchmarking
  • Figure 10.1 Grant Analysis: Cumulative Year-wise Distribution of Grants Awarded, 2017-2022
  • Figure 10.2 Grant Analysis: Cumulative Year-wise Distribution by Amount Awarded (USD Million), 2017-2022
  • Figure 10.3 Grant Analysis: Distribution by Administering Institute Center
  • Figure 10.4 Grant Analysis: Distribution by Support Period
  • Figure 10.5 Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 10.6 Grant Analysis: Distribution by Type of Grant Application
  • Figure 10.7 Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 10.8 Grant Analysis: Distribution by Activity Code
  • Figure 10.9 Word Cloud: Emerging Focus Areas
  • Figure 10.10 Grant Analysis: Distribution by Study Section Involved
  • Figure 10.11 Popular NIH Departments: Distribution by Number of Grants
  • Figure 10.12 Grant Analysis: Distribution by Types of Recipient Organization
  • Figure 10.13 Most Prominent Program Officers: Distribution by Number of Grants
  • Figure 10.14 Popular Recipient Organization: Distribution by Number of Grants
  • Figure 10.15 Grant Analysis: Regional Distribution of Recipient Organization
  • Figure 11.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2017-2022
  • Figure 11.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2017-2022
  • Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2017-2022
  • Figure 11.4 Funding and Investment Analysis: Distribution of the Total Amount Invested (USD Million) by Type of Funding, 2017-2022
  • Figure 11.5 Most Active Players: Distribution by Number of Funding Rounds and Amount Raised
  • Figure 11.6 Most Active Investors: Distribution by Number of Instances
  • Figure 11.7 Funding and Investment Analysis: Regional Distribution of Total Amount Invested, 2017-2022
  • Figure 12.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2017-2022
  • Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
  • Figure 12.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, 2017-2022
  • Figure 12.5 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 12.6 Partnerships and Collaborations: Distribution by Application Area
  • Figure 12.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 12.8 Partnerships and Collaborations: Regional Distribution
  • Figure 12.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 13.1 Startup-Health Indexing: Distribution by Location of Headquarters
  • Figure 13.2 Startup-Health Indexing: Distribution by Pipeline Strength
  • Figure 13.3 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Figure 13.4 Startup-Health Indexing: Distribution by Indication Diversity
  • Figure 13.5 Startup-Health Indexing: Distribution by Number of Patents
  • Figure 13.6 Startup-Health Indexing: Distribution by Funding Amount
  • Figure 13.7 Start-up Health Indexing: Roots Analysis Perspective
  • Figure 13.8 Start-up Health Indexing: Leading Companies
  • Figure 14.1 Global Bacteriophage Therapeutics Market, 2022-2035 (USD Million)
  • Figure 14.2 Global Bacteriophage Therapeutics Market for Therapeutic Area, 2022-2035 (USD Million)
  • Figure 14.3 Bacteriophage Therapeutics Market for Gastrointestinal Infectious, 2022-2035 (USD Million)
  • Figure 14.4 Bacteriophage Therapeutics Market for Bacterial Dysentery, 2022-2035 (USD Million) 2022-2035 (USD Million)
  • Figure 14.5 Bacteriophage Therapeutics Market for Multiple Infections, 2022-2035 (USD Million)
  • Figure 14.6 Bacteriophage Therapeutics Market for Other Infections, 2022-2035 (USD Million)
  • Figure 14.7 Global Bacteriophage Therapeutics Market for Route of Administration, 2022-2035 (USD Million)
  • Figure 14.8 Bacteriophage Therapeutics Market for Oral Therapies, 2022-2035 (USD Million)
  • Figure 14.9 Bacteriophage Therapeutics Market for Rectal Therapies, 2022-2035 (USD Million)
  • Figure 14.10 Bacteriophage Therapeutics Market for Intravesical Therapies, 2022-2035 (USD Million)
  • Figure 14.11 Global Bacteriophage Therapeutics Market for Regional Distribution, 2022-2035 (USD Million)
  • Figure 14.12 Bacteriophage Therapeutics Market in North America, 2022-2035 (USD Million)
  • Figure 14.13 Bacteriophage Therapeutics Market in North America, 2022-2035 (USD Million)
  • Figure 14.14 Bacteriophage Therapeutics Market in Europe, 2022-2035 (USD Million)
  • Figure 14.15 Complex Pyobacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.16 Dysentery Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.17 E.coli-Proteus Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.18 Enko BACTERIOPHAGE: Sales Forecast till 2035 (USD Million)
  • Figure 14.19 Fersisi BACTERIOPHAGE: Sales Forecast till 2035 (USD Million)
  • Figure 14.20 Intesti: Sales Forecast till 2035 (USD Million)
  • Figure 14.21 Intesti Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.22 Klebsiella Purified Polyvalent Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.23 Pyo Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.24 SES Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.25 Sextaphag®: Sales Forecast till 2035 (USD Million)
  • Figure 14.26 Staphylococcal Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.27 Streptococcus Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.28 Pyo Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.29 PYO Phage Streptococcus Bacteriophage: Sales Forecast till 2035 (USD Million)
  • Figure 14.30 Unnamed Streptococcus Bacteriophage (Adaptive Phage Therapeutics): Sales Forecast till 2035 (USD Million)
  • Figure 15.1 Concluding Remarks: Market Landscape
  • Figure 15.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 15.3 Concluding Remarks: Patent Analysis
  • Figure 15.4 Concluding Remarks: Publication Benchmarking Analysis
  • Figure 15.5 Concluding Remarks: Academic Grants Analysis
  • Figure 15.6 Concluding Remarks: Funding and Investment Analysis
  • Figure 15.7 Concluding Remarks: Partnerships and Collaborations
  • Figure 15.8 Concluding Remarks: Start-up Health Indexing
  • Figure 15.9 Concluding Remarks: Market Sizing and Opportunity Analysis